Literature DB >> 10886538

Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study.

F Z Al-Faleh1, A Aljumah, M Rezeig, M Al-Otaibi, M Alahdal, S Al-Humayed, I Mayet, M Al-Juhani, M Al-Karawi, K George, F Sbeih.   

Abstract

Between 1996 and 1997, we conducted a multicentre study to assess the effect of combination therapy of interferon (IFN) + ribavirin on chronic hepatitis C genotype 4. Ninety-seven patients were enrolled. Sixty-eight patients (47 male and 21 female) were non-responders to previous therapy with IFN (Group I). Twenty-nine patients (19 male and 10 female) were new (Group II). Following treatment with IFN, 23% in Group I and 9% in Group II had a sustained biochemical response. Only 12% in Group I and 5% in Group II achieved a sustained virological response. Virus load was found to be the major factor determining response, followed by histology grading and staging. Like HCV genotype 1, HCV genotype 4 seems to have a poor response to therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10886538     DOI: 10.1046/j.1365-2893.2000.00213.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy.

Authors:  S J Polyak; K S Khabar; M Rezeiq; D R Gretch
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.

Authors:  M F Derbala; S R Al Kaabi; N Z El Dweik; F Pasic; M T Butt; R Yakoob; A Al-Marri; A M Amer; N Morad; A Bener
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

3.  Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.

Authors:  Abdulrahman A Aljumah; Mohamed A Saeed; Ahmed I Al Flaiw; Ibrahim H Al Traif; Abduljaleel M Al Alwan; Salem H Al Qurashi; Ghormallah A Al Ghamdi; Fayez F Al Hejaili; Mohammed A Al Balwi; Abdulla A Al Sayyari
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

4.  Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.

Authors:  Hamad Al Ashgar; Mohammed Q Khan; Ahmed Helmy; Khalid Al Swat; Abdullah Al Shehri; Abdalla Al Kalbani; Musthafa Peedikayel; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Mohammed Al Fadda
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

5.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

6.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

7.  Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.

Authors:  Ayman A Abdo; Faisal M Sanai
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

Review 8.  The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Hossein Ghaderi-Zefrehi; Mohammad Gholami-Fesharaki; Heidar Sharafi; Farzin Sadeghi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-08-23       Impact factor: 0.660

Review 9.  Prevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence.

Authors:  Suhair M Abozaid; Mohamed Shoukri; Ahmad Al-Qahtani; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2013 Jan-Feb       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.